

Original article

## Lipid profile and persistent lipid abnormalities in diabetic patients – a retrospective study

Ana Margarida Monteiro<sup>a,\*</sup>, Isabel Palma<sup>b</sup><sup>a</sup> Department of Endocrinology, Hospital de Braga, Braga, Portugal<sup>b</sup> Department of Endocrinology, Centro Hospitalar do Porto, Porto, Portugal

## ARTICLE INFO

## Article history:

Received 1 March 2016

Accepted 16 June 2016

Available online 12 July 2016

## Keywords:

Diabetes mellitus

Dyslipidemia

Statins

## ABSTRACT

**Introduction:** The purposes of this study are the characterization the lipid profile and the suitability of the statins treatment according to the cardiovascular profile. Also, in statin-treated patients, we aim to determine the prevalence of persistent lipid abnormalities.

**Material and methods:** Observational and retrospective study of outpatient diabetic patients of a hospital consultation, between Jun/2014 and Jun/2015.

**Results:** Of the 199 diabetic patients included, 58.6% were treated with statins and only 13.9% were treated with statin dose adequate for its cardiovascular profile. The patients without overt cardiovascular disease had higher total cholesterol (178.0 vs 157.5 mg/dl;  $p=0.003$ ), HDL-C (51.0 vs 43.0 mg/dl;  $p=0.005$ ), LDL-C (97.0 vs 79.0 mg/dl;  $p=0.004$ ) and non-HDL-C (127.0 vs 112.5 mg/dl;  $p=0.04$ ) and higher prevalence of patients who achieved HDL-C goals (64.3 vs 33.3%;  $p<0.0001$ ). Almost half of statin-treated patients (46.8%) failed to achieve the LDL-C goals, 35.8% and 51.6% failed the triglycerides and HDL-C goals, respectively. Only 11.7% achieved all three goals. In statin-treated patients, we found a statistically significant difference between patients with and without cardiovascular disease on the prevalence of patients reaching the target HDL-C (68.1 vs 35.4%;  $p=0.001$ ). There were no differences in the prevalence of patients who achieved LDL-C and triglyceride goals.

**Discussion/conclusion:** There is a suboptimal utilization of statins and a substantial percentage of diabetic patients that do not achieve the therapeutic goals. We emphasize the need for an effort to optimize the lipid profile of diabetics in order to contribute to reducing the prevalence of cardiovascular diseases in this population.

© 2016 Sociedade Portuguesa de Endocrinologia, Diabetes e Metabolismo. Published by Elsevier España, S.L.U. This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).

## Perfil lipídico e persistência de anomalias lipídicas em doentes diabéticos – um estudo retrospectivo

## RESUMO

**Introdução:** Os objetivos são a caracterização do perfil lipídico e a avaliação do tratamento com estatinas de acordo com o perfil cardiovascular. Adicionalmente, pretendemos determinar prevalências de anomalias lipídicas persistentes nos doentes tratados com estatinas.

**Materiais e métodos:** Estudo observacional e retrospectivo de diabéticos acompanhados numa consulta hospitalar entre 06/2014 e 06/2015.

**Resultados:** Dos 199 doentes, 58,6% estavam tratados com estatinas e 13,9% estavam tratados com doses de estatinas adequadas para o perfil cardiovascular. Os doentes sem doença cardiovascular (DCV) tinham níveis mais elevados de colesterol total (178,0 vs. 157,5 mg/dl;  $p=0,003$ ), HDL-C (51,0 vs. 43,0 mg/dl;  $p=0,005$ ), LDL-C (97,0 vs. 79,0 mg/dl;  $p=0,004$ ), e não-HDL-C (127,0 vs. 112,5 mg/dl;  $p=0,04$ ) e uma maior prevalência de doentes que alcançaram metas de HDL-C (64,3 vs. 33,3%;  $p<0,0001$ ). Quase metade dos doentes tratados com estatinas (46,8%) não atingiram o valor alvo de LDL-C, 35,8 e 51,6% falharam as metas de HDL-C e de triglicéridos, respetivamente. Apenas 11,7% atingiram todos os 3 objetivos. Nos

**Palavras-chave:**  
Diabetes mellitus  
Dislipidemia  
Estatinas

\* Corresponding author.

E-mail addresses: [anamargaridacmonteiro@gmail.com](mailto:anamargaridacmonteiro@gmail.com), [ana.m.monteiro@hospitaldebraga.pt](mailto:ana.m.monteiro@hospitaldebraga.pt) (A.M. Monteiro).

doentes tratados com estatinas, encontramos diferença estatisticamente significativa entre os doentes com e sem DCV, sobre a prevalência de atingimento do alvo HDL-C (68,1 vs. 35,4%,  $p=0,001$ ). Não houve diferenças na prevalência de doentes que atingiram os objetivos de LDL-C e triglicéridos.

**Discussão e conclusão:** Verifica-se uma utilização subótima das estatinas e uma percentagem substancial de diabéticos que não alcançam os objetivos terapêuticos. Salienta-se a necessidade de um esforço para otimizar o perfil lipídico dos diabéticos de forma a contribuir para a diminuição da prevalência de DCV nesta população.

© 2016 Sociedade Portuguesa de Endocrinologia, Diabetes e Metabolismo. Publicado por Elsevier España, S.L.U. Este é um artigo Open Access sob uma licença CC BY-NC-ND (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).

## Introduction

Cardiovascular disease (CVD) is the leading cause of death among adult diabetic patients.<sup>1</sup> Although the multifactorial etiology of atherosclerotic vascular disease, dyslipidemia is a common and an important predictor of cardiovascular risk.<sup>2</sup> Dyslipidemia is usually present at diagnosis of type 2 diabetes and persists regardless of the treatment of hyperglycemia. The main therapy goal in the management of dyslipidemia is to decrease the levels of LDL-cholesterol (LDL-C) and other apolipoprotein-B-containing lipoproteins, which is primarily achieved with dietary modifications and statins.<sup>3,4</sup>

Data from randomized controlled trials of statin therapy show highly significant reductions in the incidence of major CVD events in diabetic patients, with or without established CVD. Moreover, the reductions in major CVD events are proportional to the reduction in LDL cholesterol. Despite the widespread evidence of the benefits of lipid-lowering treatment, particularly with statins, for reducing cardiovascular disease and mortality in diabetic patients, a considerable proportion of diabetic patients do not achieve the therapeutic goals in LDL cholesterol.<sup>5,6</sup>

The aim of this study is to characterize lipid profile of diabetic patients, according the presence or absence of previous cardiovascular event and the evaluation of the suitability of the treatment with statins according to the cardiovascular profile. Additionally, our purpose is to determine in the statin-treated patients, the prevalence of persistent lipid abnormalities.

## Material and methods

### Data sources and subjects

This article describes an observational, analytical and retrospective study of outpatient diabetic patients followed at Educational Therapy of Diabetes Consultation (CTED) in *Centro Hospitalar do Porto* (CHP), between June 2014 and June 2015. CTED is a multidisciplinary consultation composed of endocrinologists, nurses, nutritionists, psychologists and podiatrists. The main purpose of this consult is diabetes self-management education and support. The patients are referenced to this consult by family physician or by another specialty consultation in HSA.

Outpatients eligible for inclusion were age  $\geq 18$  years old. Patients were excluded if they were type 1 diabetic and if it was impossible to obtain the file of the patient. The source of information was electronic or paper file.

### Data collection

Data were collected from medical records and clinical examination at the time of the consults. Demographics (age and gender) and anthropometric variables [weight, height and body mass index (BMI)] were recorded at first visit, as well as glycosylated hemoglobin (DCA2000 method). Lipid profile [total

cholesterol (TC), triglycerides (TG), LDL-C, HDL-cholesterol (HDL-C) and apolipoprotein B (apoB)] were obtained on the second visit. The measurements were made in the same laboratory, by standard hospital assays – CT, HDL-C and TG through enzymatic methods (Roche®) in freshly drawn lithium-heparin plasma samples. The value of LDL-C was calculated using the Friedewald equation ( $LDL-C = TC - HDL-C - [TG/5]$ ), if TG levels  $< 400$  mg/dl and measured directly at higher levels. Non-HDL cholesterol (non HDL-C) was also calculated ( $TC - HDL-C$ ). Apolipoproteins were measured through immunoturbidimetric assays. Because of its influence on lipid profile, we excluded thyroid dysfunction in all patients through TSH measurement by electrochemiluminescence.

The presence of cardiovascular risk factors (smoking, hypertension, dyslipidemia and physical inactivity), of diabetic kidney disease and history of cardiovascular disease (ischemic heart disease, cerebrovascular disease and peripheral artery disease) were registered.

### Definition of dyslipidemia

To determine the persistence of lipid abnormalities, in terms of dyslipidemia treatment and goals of lipid levels, it was applied the American Diabetes Association (ADA) recommendations of 2014. Accordingly, patients without overt CVD the goal of LDL-C is less than 100 mg/dl, and in individuals with overt CVD the goal of LDL-C is less than 70 mg/dl. Although the LDL-target statin therapy is the preferred strategy, additional targets are triglyceride levels less than 150 mg/dl and HDL-C superior to 40 or 50 mg/dl, in men and women, respectively.<sup>7</sup>

The lipid levels goals correspond to a range of values defined by an upper limit without a lower limit. Although the term target is commonly used interchangeably, achieving targets could result in the undertreatment of many patients who could benefit from having LDL-C, triglyceride values below the target values or HDL-C above the target value.

To analyze the suitability of the dose of statins were used the recommendations of the ADA in 2015. Therefore, diabetic patients were divided in groups considering the age and the presence or absence of overt CVD [previous cardiovascular events or acute coronary syndromes] and cardiovascular (CV) risk factors [LDL  $\geq 100$  mg/dl, high blood pressure, smoking, overweight or obesity]. Patients of all ages with diabetes and overt CVD should be medicated with an high-dose statin. Patients with diabetes under 40 years of age and with additional CVD risk factors, it should be considered using moderate or high-dose statin. For patients with diabetes aged 40–75 years without additional CVD risk factors, it should be considered using moderate-dose statin. For patients with diabetes aged 40–75 years with additional CVD risk factors, it should be considered using high-dose statin. For diabetics over 75 years old without additional CVD risk factors, it should be considered using moderate-dose statin therapy. And for patients over 75 years with additional CVD risk factors, it should be considered using moderate or high-dose statin therapy.<sup>8</sup>

The statins were classified in high-intensity and moderate-intensity according to the potency for lowering LDL-C. High-intensity statins lowers LDL-C by 50% (atorvastatin 40 mg, atorvastatin 80 mg, rosuvastatin 20 mg and rosuvastatin 40 mg). Moderate-intensity statins lowers LDL-C 30–50% (atorvastatin 10 mg, atorvastatin 20 mg, rosuvastatin 5 mg, rosuvastatin 10 mg, simvastatin 20 mg, simvastatin 40 mg, pravastatin 40 mg, pravastatin 80 mg, lovastatin 40 mg, fluvastatin XL 80 mg, fluvastatin 40 mg bid, pitavastatin 2 mg, pitavastatin 4 mg).<sup>8</sup>

### Statistical analysis

Continuous variables are expressed as the mean and standard deviation (SD) or median and interquartile range (IQR) (25th–75th percentile), according to the distribution of variables. Age was the only continuous variable with a normal distribution and was expressed as mean and SD. The others continuous variables had a non-normal distribution and were expressed as median and IQR. Categorical variables are expressed as frequencies, percentages and confidence interval of 95% (95% CI). Group comparisons were made using the Mann–Whitney *U* test or the Wilcoxon rank-sum test for continuous variables and the chi-square ( $\chi^2$ ) test for categorical variables. Statistical significance was defined at  $p < 0.05$ . Statistical analysis was performed using SPSS™ software version 20.

### Results

The study included 199 diabetic patients with a mean age of  $59.0 \pm 9.6$  years and with a preponderance (56.8%;  $n = 113$ ) of males. In this population, type 2 diabetes was the predominant type of diabetes (94.0%;  $n = 187$ ) and the median HbA1c were 8.0% IQR 2.2. The majority of these patients was overweight (BMI  $\geq 25$ ) (77.0%;  $n = 131$ ) and had a sedentary lifestyle (69.4%;  $n = 136$ ). Also, we found a high prevalence of dyslipidemia (77.7%;  $n = 153$ ) and hypertension (70.2%;  $n = 139$ ). More than a third (33.3%;  $n = 66$ ) had a previous cardiovascular event and 58.6% ( $n = 109$ ) were treated with statins (Table 1).

The study population was divided in two groups according to the presence or absence of previous cardiovascular event, as shown in Table 2. There were no differences between the groups in terms of age, sex, metabolic control (HbA1c) and prevalence of obesity. The group of patients with previous cardiovascular events had higher prevalence of dyslipidemia (87.7 vs 72.7%;  $p = 0.02$ ), hypertension (87.9 vs 61.4%;  $p < 0.0001$ ) and was more frequently statin-treated (87.5 vs 43.4%;  $p < 0.0001$ ).

The group of patients without overt CVD had higher TC (178.0 vs 157.5 mg/dl;  $p = 0.003$ ), HDL-C (51.0 vs 43.0 mg/dl;  $p = 0.005$ ), LDL-C

**Table 1**

The characteristics of study population ( $n = 199$ ).

Variables	Results
Age (years), mean $\pm$ SD	59.0 $\pm$ 9.6
Male, %, (95% CI), (n/N)	56.8 (47.8–63.1) (113/199)
T2DM, %, (95% CI), (n/N)	94.0 (89.8–96.8) (187/199)
HbA1c (%), median; IQR	8.0; 2.2
Current smoker, %, (95% CI), (n/N)	9.7 (3.8–12.7) (19/196)
Sedentary lifestyle, %, (95% CI), (n/N)	69.4 (61.1–75.8) (136/196)
BMI, median; IQR	28.7; 6.3
Overweight (BMI $\geq 25$ and $< 30$ ), %, (95% CI), (n/N)	38.2 (30.6–45.9) (65/170)
Obesity (BMI $\geq 30$ ), %, (95% CI), (n/N)	38.8 (32.5–47.8) (66/170)
Dyslipidemia, %, (95% CI), (n/N)	77.7 (75.8–87.9) (153/197)
Hypertension, %, (95% CI), (n/N)	70.2 (66.2–80.9) (139/198)
CAD, cerebrovascular disease and/or PAD, %, (95% CI), (n/N)	33.3 (28.0–42.7) (66/198)
Statin-treated, %, (95% CI), (n/N)	58.6 (54.8–69.4) (109/186)

BMI: body mass index; CAD: coronary artery disease; PAD: peripheral artery disease; T2DM: type 2 diabetes mellitus.

(97.0 vs 79.0 mg/dl;  $p = 0.004$ ) and non-HDL (127.0 vs 112.5 mg/dl;  $p = 0.04$ ) and higher prevalence of patients who achieved HDL-C goals (64.3 vs 33.3%;  $p < 0.0001$ ), as demonstrated in Table 3. There were no statistical differences on the median of the triglycerides and of the apo-B.

A strong and positive correlation between apo-B and non-HDL-C was verified ( $r = 0.87$ ;  $p < 0.001$ ).

The group of patients without overt CVD had significantly higher prevalence of patients that met the HDL-C goals (64.3 vs 33.3%;  $p < 0.0001$ ). Although, we found no statistical difference on prevalence of patients that met the LDL-C and TG goals.

The study of suitability of the dose of the statin has shown that there were no differences between the groups (14.1 vs 6.6%;  $p = 0.095$ ).

To evaluate the persistence of lipid abnormalities, the patients were divided in statin-treated and non-statin treated.

In statin-treated patients, 13.9% were treated with statins with adequate potency to their cardiovascular profile. There were no differences between the patients with and without overt CVD in the adequacy of statin treatment (Table 4). Less than half (46.8%,  $n = 44$ ) failed to achieve the LDL-C goal. Half (51.1%;  $n = 48$ ) and 35.1% ( $n = 33$ ) of these patients failed to achieve HDL-C and TG goals, respectively. Only 11.7% ( $n = 11$ ) of these patients achieved all three goals. In this group of patients, we found a statistically significant difference between those with and without cardiovascular disease in HDL-C median level (43.0 vs 50.5;  $p = 0.003$ ) and in the prevalence of patients reaching the target of HDL-C (68.1 vs 35.4%;  $p = 0.001$ ). There were no differences in the prevalence of patients who achieved LDL-C and triglyceride goals (Table 4).

**Table 2**

Characteristics of the groups: with and without overt CVD.

Variables	Overt CVD ( $n = 66$ )	Non-CVD ( $n = 132$ )	All ( $n = 199$ )	<i>p</i> Value*
Age (years), mean $\pm$ SD	60.4 $\pm$ 9.2	58.2 $\pm$ 9.7	59.0 $\pm$ 9.6	0.1
Male, %, (95% CI) (n/N)	54.5 (37.8–68.2) (36/66)	58.3 (44.4–63.9) (77/132)	56.8 (47.8–63.1) (113/199)	0.6
T2DM, %, (95% CI) (n/N)	98.5 (92.5–100.0) (65/66)	91.7 (85.9–96.1) (121/132)	94.0 (89.8–96.8) (187/199)	0.4
HbA1c (%), median; IQR	8.1; 2.2	8.0; 2.3	8.0; 2.2	0.5
Current smoker, %, (95% CI) (n/N)	10.6 (2.5–21.7) (7/66)	9.2 (2.0–12.1) (12/130)	9.7 (3.8–12.7) (19/196)	0.8
Sedentary lifestyle, %, (95% CI) (n/N)	74.2 (69.8–93.0) (49/66)	66.9 (57.6–75.3) (87/130)	69.4 (61.1–75.8) (136/196)	0.3
BMI, median; IQR	28.9; 6.5	28.6; 6.5	28.7; 6.3	0.08
Overweight (BMI $\geq 25$ and $< 30$ ), %, (95% CI) (n/N)	46.6 (29.7–57.9) (27/58)	33.3 (24.2–43.0) (37/111)	38.2 (30.6–45.9) (65/170)	0.09
Obesity (BMI $\geq 30$ ), %, (95% CI) (n/N)	41.4 (32.6–61.4) (24/58)	37.8 (28.6–47.4) (42/111)	38.8 (32.5–47.8) (66/170)	0.7
Dyslipidemia, %, (95% CI) (n/N)	87.7 (81.8–98.0) (57/65)	72.7 (68.6–85.0) (96/132)	77.7 (75.8–87.9) (153/197)	0.02
Hypertension, %, (95% CI) (n/N)	87.9 (81.8–98.0) (58/66)	61.4 (56.6–75.2) (81/132)	70.2 (66.2–80.9) (139/198)	<0.0001
Statin-treated, %, (95% CI) (n/N)	87.5 (85.4–100.0) (56/64)	43.4 (36.3–55.8) (53/122)	58.6 (54.8–69.4) (109/186)	<0.0001

BMI: body mass index; CAD: coronary artery disease; CVD: cardiovascular disease; PAD: peripheral artery disease; T2DM: type 2 diabetes mellitus.

\* Statistical significance:  $p < 0.05$ .

**Table 3**  
Lipid profile in diabetics with and without overt CVD.

Lipid profile	Overt CVD	Non-CVD	All	p Value*
Total cholesterol (mg/dl), median; IQR	157.5; 51.8	178.0; 58.0	172.5; 58.5	0.003
Triglycerides (mg/dl), median; IQR	129.5; 99.8	113.0; 82.3	117.0; 85.3	0.3
HDL-C (mg/dl), median; IQR	43.0; 14.0	51.0; 24.0	47.0; 23.0	0.005
LDL-C (mg/dl), median; IQR	79.0; 45.0	97.0; 50.0	89.0; 49.5	0.004
Apo-B (mg/dl), median; IQR	82.0; 39.8	92.0; 33.0	90.0; 33.8	0.08
Non-HDL-C (mg/dl), median; IQR	112.5; 45.5	127.0; 53.0	117.0; 52.3	0.04
Patients at LDL-C goal, <sup>a</sup> %, 95% CI, (n/N)	39.6 (24.0–51.2) (21/53)	52.2 (39.6–61.2) (60/115)	48.2 (81/168)	0.13
Patients at TG goal, <sup>b</sup> %, 95% CI, (n/N)	63.0 (47.9–76.5) (34/54)	70.4 (61.1–80.4) (81/115)	67.6 (115/170)	0.3
Patients at HDL-C goal, <sup>c</sup> %, 95% CI, (n/N)	33.3 (18.4–44.9) (18/54)	64.3 (56.5–76.0) (74/115)	54.1 (92/170)	<0.0001
Patients achieving all goals (LDL-C, HDL-C and TG), %, 95% CI, (n/N)	5.7 (0.0–11.4) (3/53)	9.6 (3.2–14.9) (11/115)	8.3 (14/168)	0.4
Patients with adequate statin-treatment, %, 95% CI, (n/N)	14.1 (4.5–23.9) (9/64)	6.6 (2.1 – 12.0) (8/121)	9.1 (17/186)	0.095

CVD: cardiovascular disease.

<sup>a</sup> LDL-C goal: <70 mg/dl and <100 mg/dl in patients with and without overt CVD, respectively.<sup>b</sup> TG goal: <150 mg/dl.<sup>c</sup> HDL-C goal: > 40 or 50 mg/dl, in men and women, respectively.\* Statistical significance:  $p < 0.05$ .**Table 4**  
Persistence of lipid abnormalities.

Lipid profile	Statin-treated			p Value*
	Overt CVD	Non-CVD	All (n = 109)	
Adequate statin, % (n/N)	16.1 (6.5–26.0) (9/56)	11.5 (3.9–20.8) (6/52)	13.9 (5.4–13.4) (15/108)	0.5
Total cholesterol (mg/dl), median; IQR	156.0; 58.0	172.0; 53.8	162.0; 48.0	0.13
Triglycerides (mg/dl), median; IQR	134.0; 96.0	126.5; 74.0	130.0; 84.0	0.4
HDL-C (mg/dl), median; IQR	43.0; 14.0	50.5; 18.8	45.0; 19.0	0.003
LDL-C (mg/dl), median; IQR	77.5; 46.3	86.5; 45.8	83.0; 48.8	0.2
Apo-B (mg/dl), median; IQR	82.0; 39.0	90.0; 25.0	85.0; 30.5	0.4
Non-HDL (mg/dl), median; IQR	113.0; 50.0	115.0; 46.5	113.0; 48.0	0.4
Patients not at LDL-C goal, <sup>a</sup> % (95% CI) (n/N)	56.5 (35.7–67.5) (26/46)	37.5 (24.3 – 52.4) (18/48)	46.8 (33.7–55.4) (44/95)	0.07
Patients not at TG goal, <sup>b</sup> % (95% CI) (n/N)	38.3 (24.1–55.6) (18/47)	33.3 (20.9–48.4) (16/48)	35.8 (26.0–46.9) (34/95)	0.6
Patients not at HDL-C goal, <sup>c</sup> % (95% CI) (n/N)	68.1 (50.0–79.1) (32/47)	35.4 (22.0–50.0) (17/48)	51.6 (39.3–60.9) (49/95)	0.001
Patients achieving all goals (LDL-C, HDL-C and TG), % (n/N)	6.5 (0.0–16.7) (3/46)	16.7 (6.8–28.0) (8/48)	11.7 (5.7–19.8) (11/94)	0.1

CVD: cardiovascular disease.

<sup>a</sup> LDL-C goal: <70 mg/dl and <100 mg/dl in patients with and without overt CVD, respectively.<sup>b</sup> TG goal: <150 mg/dl.<sup>c</sup> HDL-C goal: > 40 or 50 mg/dl, in men and women, respectively.\* Statistical significance:  $p < 0.05$ .

## Discussion

As other similar published studies our study population included diabetic patients with a mean age in the sixties and with a high prevalence of overweight, sedentary lifestyle, dyslipidemia and hypertension.<sup>9,10</sup> Also, we found an elevated prevalence of non-statin treated patients (56.8%).

The group of patients without overt CVD was more frequently non-statin treated and had higher TC, LDL-C, HDL-C and non-HDL. Also, there was a trend for statistical significance to higher apo-B levels.

In the Dyslipidemia International Study (DYSIS) the diabetics without a previous CVD also had higher LDL-C and HDL-C.<sup>10</sup> Those facts may reflect better lipid-focused treatment in patients with a previous event of CVD. The group of patients without previous CVD had significantly higher prevalence of patients that achieved the HDL-C goals, and this is concordant with the findings of DYSIS.<sup>10</sup> A higher level HDL-C in patients without overt CVD can be the reflection of their cardioprotective effect.

In our study, half of the statin-treated diabetic patients (53.2%) achieved LDL-C goals. This finding is similar to the analysis of Leiter et al. and Feher et al., however are in contrast with the analysis of Silva et al. of Portuguese subpopulation of the DYSIS (77.1%).<sup>9–11</sup> We verified that over one third (35.8%) did not achieved TG goals, half (51.6%) did not achieved HDL-C goals and only a minority (11.7%) of patients achieved all three goals. In the Portuguese subpopulation

analysis of DYSIS the percentage of patients that not met the TG goals are similar (41.4%) but diverge on the percentage of patients that failed the HDL-C goal (27.7%).<sup>9</sup> In DYSIS, a quarter (25.9%) of the diabetic patients and almost 20% (19.9%) did not achieve TG and HDL-C goals, respectively, and 39% of the patients achieve all goals.<sup>10</sup> Feher et al. demonstrated that approximately half of the patients who received statin monotherapy attained the treatment goals for HDL-C and TG.<sup>11</sup>

When analyzing the suitability of the dose of the statin we verified that there were no differences between the groups, although with a tendency to significance for the group with overt CVD. This can be the expression, again, of a higher attention to lipid treatment in patients with a previous event of CVD.

The vast majority of patients were treated with a dose of statin non-adequate to their cardiovascular profile. This observation must be analyzed very carefully because the study included patients observed from June 2014 to June 2015. As this recommendations were published in November 2013 by the ACC/AHA and adopted by ADA in January 2015, we cannot make firm conclusions about the suitability of statins dose, and this is a considerable limitation of the study.

## Limitations

This study reflects a small sample of patients evaluated in the CTED, analyzed retrospectively and we did not evaluate long-term

outcomes. In addition, we lack data of adherence to treatment regime or contraindications to statin therapy.

### Conclusion

Several clinical studies have demonstrated evidence supporting the beneficial effects of statins therapy in patients for both primary and secondary prevention of CVD events and death. Also, recommendations of treatment and management of dyslipidemia are wide spread to guide medical decision. Despite those facts, evidence has shown, in concordance to our results, a suboptimal use of lipid-modifying therapies and a substantial percentage of diabetic patients that do not achieve the therapeutic goals. We emphasize that is necessary an effort to optimize the lipid profile of diabetic patients and, consequently, decrease the prevalence of CVD events in this population.

### Ethical disclosures

**Protection of human and animal subjects.** The authors declare that no experiments were performed on humans or animals for this study.

**Confidentiality of data.** The authors declare that no patient data appear in this article.


**Right to privacy and informed consent.** The authors declare that no patient data appear in this article.

### Conflicts of interest

The authors have no conflicts of interest to declare.

### References

1. Preis SR, Pencina MJ, Hwang SJ, D'Agostino RB Sr, Savage PJ, Levy D, et al. Trends in cardiovascular disease risk factors in individuals with and without diabetes mellitus in the Framingham Heart Study. *Circulation*. 2009;120(3):212–20.
2. Task Force M, Ryden L, Grant PJ, Anker SD, Berne C, Cosentino F, et al. ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD: the Task Force on diabetes, pre-diabetes, and cardiovascular diseases of the European Society of Cardiology (ESC) and developed in collaboration with the European Association for the Study of Diabetes (EASD). *Eur Heart J*. 2013;34(39):3035–87.
3. Betteridge DJ. Lipid control in patients with diabetes mellitus. *Nat Rev Cardiol*. 2011;8(5):278–90.
4. Wu L, Parhofer KG. Diabetic dyslipidemia. *Diabetic dyslipidemia. Metab: Clin Exp*. 2014;63(12):1469–79.
5. Kotseva K, Wood D, De Backer G, De Bacquer D, Pyorala K, Keil U, et al. EUROASPIRE III: a survey on the lifestyle, risk factors and use of cardioprotective drug therapies in coronary patients from 22 European countries. *Eur J Cardiovasc Prevent Rehab: Off J Eur Soc Cardiol, Epidemiol Prevent Cardiac Rehabil Exerc Physiol*. 2009;16(2):121–37.
6. Gitt AK, Drexel H, Feely J, Ferrieres J, Gonzalez-Juanatey JR, Thomsen KK, et al. Persistent lipid abnormalities in statin-treated patients and predictors of LDL-cholesterol goal achievement in clinical practice in Europe and Canada. *Eur J Prevent Cardiol*. 2012;19(2):221–30.
7. Standards of medical care in diabetes – 2014. *Diabetes Care*. 2014; 37 Suppl 1:S14–80. Epub 2013/12/21.
8. Standards of medical care in diabetes – 2015: summary of revisions. *Diabetes Care*. 2015;38 Suppl:S4. Epub 2014/12/30.
9. da Silva PM, Cardoso SM, Ferreira AM. Persistent lipid abnormalities in statin-treated patients: Portuguese diabetic subpopulation of the Dyslipidaemia International Study (DYSIS). *Prim Care Diab*. 2015;9(4):283–9. Epub 2014/12/03.
10. Leiter LA, Lundman P, da Silva PM, Drexel H, Junger C, Gitt AK. Persistent lipid abnormalities in statin-treated patients with diabetes mellitus in Europe and Canada: results of the Dyslipidaemia International Study. *Diabet Med*. 2011;28(11):1343–51. Epub 2011/06/18.
11. Feher M, Greener M, Munro N. Persistent hypertriglyceridemia in statin-treated patients with type 2 diabetes mellitus. *Diabetes Metab Syndr Obes*. 2013;6:11–5. Epub 2013/01/24.



Caso clínico

Prolactinoma gigante – 3 casos clínicos e revisão da literatura



Patrícia Tavares<sup>a,\*</sup>, Gustavo Rocha<sup>a</sup>, Mário Resende<sup>b</sup>, Lino Mascarenhas<sup>b</sup> e Maria João Oliveira<sup>a</sup>

<sup>a</sup> Serviço de Endocrinologia, Centro Hospitalar Vila Nova Gaia/Espinho, Vila Nova de Gaia, Portugal

<sup>b</sup> Serviço de Neurocirurgia, Centro Hospitalar Vila Nova Gaia/Espinho, Vila Nova de Gaia, Portugal

INFORMAÇÃO SOBRE O ARTIGO

Historial do artigo:

Recebido a 1 de maio de 2015

Aceite a 13 de outubro de 2015

Palavras-chave:

Prolactinomas gigantes

Agonistas dopaminérgicos

Cabergolina

R E S U M O

Os prolactinomas gigantes são tumores raros, mais frequentes em homens, cujos critérios de diagnóstico incluem adenoma hipofisário com maior eixo igual ou superior a 4 cm e extensão extrasselar, valor sérico de prolactina  $\geq 1.000$  ng/mL e exclusão de secreção concomitante de hormona de crescimento (HC) ou corticotrofina (ACTH).

São descritos 3 casos de prolactinoma gigante, todos em doentes do sexo masculino com idades ao diagnóstico de 20, 41 e 75 anos.

O sintoma de apresentação foi cefaleia em 2 casos (uma associada a perda de visão do OE) e o terceiro caso foi um diagnóstico incidental. O doseamento de prolactina era superior a 4.700 ng/mL em todos os casos, associado a um hipogonadismo hipogonadotrófico. O tamanho médio (maior eixo) da lesão inicial foi de 4,9 cm (4–6 cm), sendo 2 dos casos submetidos a ressecção transesfenoidal ao diagnóstico. Dois doentes estão sob tratamento médico com bromocriptina e um medicado com cabergolina.

A bibliografia atual defende a opção inicial pelo tratamento médico com cabergolina, permanecendo a indicação cirúrgica para os casos resistentes, com sintomas compressivos graves ou doentes intolerantes aos agonistas dopaminérgicos.

© 2015 Sociedade Portuguesa de Endocrinologia, Diabetes e Metabolismo. Publicado por Elsevier España, S.L.U. Este é um artigo Open Access sob uma licença CC BY-NC-ND (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).

Giant prolactinoma - Three case reports and literature review

A B S T R A C T

Giant prolactinomas are rare tumors, more frequent in men and whose diagnostic criteria include pituitary adenomas with a diameter of 4 cm or more, extrasellar extension, a serum prolactin  $\geq 1,000$  ng/mL, and no concomitant growth hormone (GH) or corticotropin (ACTH) secretion.

We report on three cases of giant prolactinoma, all in male patients with an age at diagnosis of 20, 41 and 75 years.

The presenting symptom was headache in 2 cases (1 associated with vision loss of left eye) the third case was an incidental diagnosis. The prolactin assay was greater than 4700 ng/ml in all cases associated with hypogonadotropic hypogonadism. The average size (major axis) of the initial lesion was 4.9 cm (4–6 cm), 2 cases underwent trans-sphenoidal resection at diagnosis. Two patients are under medical treatment with bromocriptine and one was medicated with cabergoline.

The current literature supports the initial option for medical treatment with cabergoline, with surgical indication reserved for cases resistant to medical therapy, patients with severe compressive symptoms or intolerant to dopamine agonists.

© 2015 Sociedade Portuguesa de Endocrinologia, Diabetes e Metabolismo. Published by Elsevier España, S.L.U. This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).

Keywords:

Giant prolactinoma

Dopaminergic agonists

Cabergoline

Introdução

Os prolactinomas são os tumores da hipófise mais frequentes, com uma prevalência de 3,5–5 por 10.000 habitantes nos estudos epidemiológicos mais recentes<sup>1–4</sup>.

\* Autor para correspondência.

Correio eletrónico: patriciatavares.med@gmail.com (P. Tavares).